Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Cercek, M. D'Angelica, D. Power, M. Capanu, A. Gewirtz, D. Patel, P. Allen, Y. Fong, R. DeMatteo, W. Jarnagin, N. Kemeny (2014)
Floxuridine Hepatic Arterial Infusion Associated Biliary Toxicity Is Increased by Concurrent Administration of Systemic BevacizumabAnnals of Surgical Oncology, 21
(2016)
TAS-102, thefirst “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape? BMCCancer
C. Breedis, G. Young (1954)
The blood supply of neoplasms in the liver.The American journal of pathology, 30 5
O. Temmink, Tomohiro Emura, M. Bruin, M. Fukushima, G. Peters (2007)
Therapeutic potential of the dual‐targeted TAS‐102 formulation in the treatment of gastrointestinal malignanciesCancer Science, 98
J. Bendell, Tae Kim, B. Goh, J. Wallin, D. Oh, Sae-Won Han, Carrie Lee, M. Hellmann, J. Desai, J. Lewin, B. Solomon, L. Chow, W. Miller, J. Gainor, K. Flaherty, J. Infante, Meghna Das-Thakur, P. Foster, E. Cha, Y. Bang (2016)
Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).Journal of Clinical Oncology, 34
M. Rothenberg (2000)
Efficacy of oxaliplatin in the treatment of colorectal cancer.Oncology, 14 12 Suppl 11
N. Kemeny, D. Niedzwiecki, D. Hollis, H. Lenz, R. Warren, M. Naughton, J. Weeks, E. Sigurdson, J. Herndon, Chunfeng Zhang, R. Mayer (2006)
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 9
J. Cassidy, S. Clarke, E. Díaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T.S. Yang, F. Rivera, F. Couture, F. Sirzén, L. Saltz (2008)
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 12
(2007)
Therapeutic potential of thedual-targetedTAS-102 formulation inthetreatmentofgastrointestinalmalignancies
M. Vaiani, S. Trippoli, A. Messori (2001)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.The New England journal of medicine, 344 4
R. Siegel, K. Miller, A. Jemal (2017)
Cancer statistics, 2017CA: A Cancer Journal for Clinicians, 67
C. Cremolini, F. Loupakis, C. Antoniotti, C. Lupi, E. Sensi, S. Lonardi, S. Mezi, G. Tomasello, M. Ronzoni, A. Zaniboni, G. Tonini, C. Carlomagno, G. Allegrini, S. Chiara, M. D’amico, C. Granetto, M. Cazzaniga, L. Boni, G. Fontanini, A. Falcone (2015)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.The Lancet. Oncology, 16 13
D. Cunningham, S. Pyrhönen, R. James, C. Punt, T. Hickish, Reino Heikkila, T. Johannesen, H. Starkhammar, C. Topham, L. Awad, C. Jacques, P. Hérait (1998)
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 352
V. Heinemann, L. Weikersthal, T. Decker, A. Kiani, U. Vehling‐Kaiser, S. Al-Batran, T. Heintges, C. Lerchenmüller, C. Kahl, G. Seipelt, F. Kullmann, M. Stauch, W. Scheithauer, Jörg Hielscher, M. Scholz, S. Müller, H. Link, N. Niederle, A. Rost, H. Höffkes, M. Moehler, R. Lindig, D. Modest, Lisa Rossius, T. Kirchner, A. Jung, S. Stintzing (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.The Lancet. Oncology, 15 10
Floxuridinehepatic arterial infusionassociated biliary toxicity is increasedbyconcurrentadministrationof systemicbevacizumab
J. Uram, Hao Wang, Bjarne Bartlett, H. Kemberling, A. Eyring, A. Skora, N. Azad, D. Laheru, R. Donehower, Brandon Luber, T. Crocenzi, G. Fisher, Steven Duffy, James Lee, M. Koshiji, J. Eshleman, R. Anders, B. Vogelstein, L. Diaz (2015)
PD-1 blockade in tumors with mismatch repair deficiency.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 18_suppl
R. Mayer, E. Cutsem, A. Falcone, T. Yoshino, R. García-Carbonero, N. Mizunuma, K. Yamazaki, Y. Shimada, J. Tabernero, Y. Komatsu, A. Sobrero, E. Boucher, M. Peeters, B. Tran, H. Lenz, A. Zaniboni, H. Hochster, J. Cleary, H. Prenen, F. Benedetti, Hirokazu Mizuguchi, L. Makris, Masanobu Ito, A. Ohtsu (2015)
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.The New England journal of medicine, 372 20
F. Petrelli, S. Barni, P. Bertocchi, A. Zaniboni (2016)
TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?BMC Cancer, 16
D. Le, J. Uram, Hao Wang, Bjarne Bartlett, H. Kemberling, A. Eyring, A. Skora, Brandon Luber, N. Azad, D. Laheru, B. Biedrzycki, R. Donehower, A. Zaheer, G. Fisher, T. Crocenzi, James Lee, Steven Duffy, R. Goldberg, A. Chapelle, M. Koshiji, F. Bhaijee, T. Huebner, R. Hruban, L. Wood, N. Cuka, D. Pardoll, N. Papadopoulos, K. Kinzler, Shibin Zhou, Toby Cornish, J. Taube, R. Anders, J. Eshleman, B. Vogelstein, L. Diaz (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.The New England journal of medicine, 372 26
S. Stintzing, P. Wirapati, H. Lenz, D. Neureiter, L. Weikersthal, T. Decker, A. Kiani, F. Kaiser, Salah-Eddin Al-Batran, T. Heintges, C. Lerchenmuller, C. Kahl, G. Seipelt, Frank Kullmann, M. Moehler, W. Scheithauer, S. Held, D. Modest, A. Jung, T. Kirchner, D. Aderka, S. Tejpar, V. Heinemann (2019)
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trialAnnals of Oncology, 30
A. Sartore-Bianchi, L. Trusolino, C. Martino, K. Bencardino, S. Lonardi, F. Bergamo, V. Zagonel, F. Leone, Ilaria Depetris, E. Martinelli, T. Troiani, F. Ciardiello, P. Racca, A. Bertotti, G. Siravegna, V. Torri, A. Amatu, S. Ghezzi, G. Marrapese, L. Palmeri, E. Valtorta, A. Cassingena, C. Lauricella, A. Vanzulli, D. Regge, S. Veronese, P. Comoglio, A. Bardelli, S. Marsoni, S. Siena (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.The Lancet. Oncology, 17 6
H. Bando, T. Doi, K. Muro, H. Yasui, T. Nishina, K. Yamaguchi, S. Takahashi, S. Nomura, H. Kuno, K. Shitara, A. Sato, A. Ohtsu (2016)
A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201).European journal of cancer, 62
P. Wilson, P. Danenberg, P. Johnston, H. Lenz, R. Ladner (2014)
Standing the test of time: targeting thymidylate biosynthesis in cancer therapyNature Reviews Clinical Oncology, 11
et al. Efficacy and circulating tumor DNA Corcoran RB (2016)
Corcoran RB, et al. Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E-mutated (BRAFm) metastatic colorectal cancer (mCRC). Ann Oncol. 2016; Abstract 455O
A. Falcone, S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini, C. Barbara, L. Crinò, G. Benedetti, W. Evangelista, L. Fanchini, E. Cortesi, V. Picone, S. Vitello, S. Chiara, C. Granetto, G. Porcile, L. Fioretto, C. Orlandini, M. Andreuccetti, G. Masi (2007)
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 13
C. Tournigand, T. André, E. Achille, G. Lledo, M. Flesh, D. Mery-mignard, E. Quinaux, C. Couteau, M. Buyse, G. Ganem, B. Landi, P. Colin, C. Louvet, A. Gramont (2023)
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 41
N. Kemeny, W. Jarnagin, M. Gonen, J. Stockman, L. Blumgart, D. Sperber, A. Hummer, Y. Fong (2003)
Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 17
C. Heidelberger, N. Chaudhuri, P. Danneberg, D. Mooren, L. Griesbach, R. Duschinsky, R. Schnitzer, E. Pleven, J. Scheiner (1957)
Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory CompoundsNature, 179
P. Thirion, S. Michiels, J. Pignon, M. Buyse, A. Braud, Robert Carlson, M. O’connell, P. Sargent, P. Piedbois (2004)
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 18
L. Saltz, J. Cox, C. Blanke, L. Rosen, L. Fehrenbacher, M. Moore, J. Maroun, S. Ackland, P. Locker, N. Pirotta, G. Elfring, L. Miller (2000)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.The New England journal of medicine, 343 13
S. Stintzing, P. Wirapati, H. Lenz, D. Neureiter, L. Weikersthal, T. Decker, A. Kiani, U. Vehling‐Kaiser, Salah-Eddin Al-Batran, T. Heintges, C. Kahl, Frank Kullmann, M. Moehler, W. Scheithauer, S. Held, D. Modest, A. Jung, T. Kirchner, S. Tejpar, V. Heinemann (2017)
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.Journal of Clinical Oncology, 35
A multicenter phase II study of TAS - 102 monotherapy in patients with pretreated advanced gastric cancer ( EPOC 1201 )
(2000)
Leucovorinandfluorouracilwithorwithout oxaliplatin as first-line treatment in advanced colorectal cancer
(2016)
Nanotech - nologies for the treatment of colon cancer : Fromold drugs tonewhope
S. Tejpar, S. Stintzing, F. Ciardiello, J. Tabernero, E. Cutsem, F. Beier, R. Esser, H. Lenz, V. Heinemann (2017)
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 TrialsJAMA Oncology, 3
(2014)
Floxuridinehepatic arterial infusionassociated biliary toxicity is increasedbyconcurrentadministrationof systemicbevacizumab.AnnSurgOncol
A. Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, C. Boni, H. Cortés-Funes, A. Cervantes, G. Freyer, D. Papamichael, N. Bail, C. Louvet, D. Hendler, F. Braud, C. Wilson, F. Morvan, A. Bonetti (2000)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 16
H. Lenz, F. Ou, A. Venook, H. Hochster, D. Niedzwiecki, R. Goldberg, R. Mayer, M. Bertagnolli, C. Blanke, T. Zemla, X. Qu, F. Innocenti, O. Kabbarah (2017)
Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).Journal of Clinical Oncology, 35
(2015)
Randomized trial of TAS102 for refractory metastatic colorectal cancer
T Andre C Tournigand (2004)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR studyJ Clin Oncol, 22
R. Corcoran, T. André, T. Yoshino, J. Bendell, C. Atreya, J. Schellens, M. Ducreux, A. McRee, S. Siena, G. Middleton, M. Gordon, Y. Humblet, K. Muro, E. Élez, R. Yaeger, R. Sidhu, M. Squires, S. Jaeger, F. Rangwala, E. Cutsem (2016)
Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)Annals of Oncology, 27
Y. Kawato, M. Aonuma, Yasuhide Hirota, Hiroshi Kuga, Keiki Sato (1991)
Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.Cancer research, 51 16
S. Kopetz, Shannon McDonough, V. Morris, H. Lenz, Anthony Magliocco, C. Atreya, Luis Diaz, Carmen Allegra, Stephen Wang, Christopher Lieu, S. Eckhardt, T. Semrad, K. Kaberle, K. Guthrie, H. Hochster (2017)
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).Journal of Clinical Oncology, 35
A. Cercek, Taryn Boucher, J. Gluskin, A. Aguiló, J. Chou, L. Connell, M. Capanu, D. Reidy‐Lagunes, M. D'Angelica, N. Kemeny (2016)
Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapiesJournal of Surgical Oncology, 114
(2008)
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plusoxaliplatinasfirst-linetherapyformetastaticcolorectal cancer
L. Kotelevets, E. Chastre, D. Desmaële, P. Couvreur (2016)
Nanotechnologies for the treatment of colon cancer: From old drugs to new hope.International journal of pharmaceutics, 514 1
Lindsey Torre, R. Siegel, E. Ward, A. Jemal (2015)
Global Cancer Incidence and Mortality Rates and Trends—An UpdateCancer Epidemiology, Biomarkers & Prevention, 25
H. Lenz, S. Stintzing, F. Loupakis (2015)
TAS-102, a novel antitumor agent: a review of the mechanism of action.Cancer treatment reviews, 41 9
R. Goldberg, D. Sargent, R. Morton, C. Fuchs, R. Ramanathan, S. Williamson, B. Findlay, H. Pitot, S. Alberts (2006)
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 21
T. Aparicio (2015)
PD-1 blockade in tumors with mismatch-repair deficiencyCôlon & Rectum, 9
Summary Substantial progress has been achieved in the management of metastatic colorectal cancer (mCRC) over the last two decades. The overall survival has increased from 10 months to more than 30 months. These improvements are due to the integration of multiple cytotoxic agents and targeted therapies, as well as individualized treatment strategies using molecular and clinical factors. More specific, molecular characteristics such as RAS mutation status and clinical factors such as performance status, tumor burden, tumor-related symptoms and comorbidities are crucial in selecting treatment strategies. Here I review the landscape of cytotoxic chemotherapy for mCRC, regional chemotherapy strategies to accumulate cytotoxics within the tumor and reflect on future directions for treatment of mCRC.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Sep 1, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.